Syndax(US:SNDX) Globenewswire·2026-02-26 21:01Core Insights - Syndax Pharmaceuticals reported total revenue of $68.7 million for Q4 2025 and $172.4 million for FY 2025, indicating strong financial performance driven by product sales [10][11] - The company completed enrollment in a Phase 2 trial for axatilimab, with topline data expected in Q4 2026, highlighting ongoing clinical development efforts [1][17] Financial Performance - Q4 2025 net revenue from Revuforj was $44.2 million, a 38% increase compared to Q3 2025, while FY 2025 revenue reached $124.8 million [4][5] - Niktimvo generated $56.0 million in net revenue for Q4 2025, a 22% increase from Q3 2025, with total FY 2025 revenue of $151.6 million [4][10] - The company reported a net loss of $68.0 million for Q4 2025, improving from a loss of $94.2 million in the same period the previous year [13] Product Development and Pipeline - Revuforj is positioned as a first-in-class menin inhibitor, with FDA approval for treating relapsed or refractory acute myeloid leukemia (AML) [19][21] - Niktimvo is a first-in-class CSF-1R-blocking antibody approved for chronic graft-versus-host disease (GVHD) after failure of prior therapies [22][25] - Multiple clinical trials for both Revuforj and Niktimvo are ongoing, with promising data presented at major medical meetings [7][8][20] Research and Development - R&D expenses for Q4 2025 increased to $78.6 million, up from $65.5 million in the prior year, reflecting the company's commitment to advancing its clinical programs [11] - The company anticipates total R&D and SG&A expenses of approximately $400 million for FY 2026, excluding non-cash stock compensation [14] Market Position and Future Outlook - The CEO emphasized the company's leadership in R&D and commercial capabilities, projecting continued growth driven by increasing uptake of Revuforj and Niktimvo [2] - Syndax expects to leverage its cash reserves and anticipated product revenues to reach profitability in the coming years [15]